Thoratec (THOR) Prelim. Q2 Revenue Tops Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Thoratec Announces Preliminary Second Quarter Revenue
July 22, 2015 7:05 AM EDTPLEASANTON, Calif., July 22, 2015 /PRNewswire/ --Â Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015.
"Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franchise," said D. Keith Grossman, President and Chief Executive Officer. "We continued to make progress with our commercial initiatives and... More
St. Jude Medical and Thoratec Announce Definitive Agreement
July 22, 2015 7:00 AM EDTCombination Accelerates Innovation-Based Growth Program and Expands Heart Failure Franchise
St. Jude Medical Will Discuss Transaction on its Second Quarter 2015 Earnings Call Scheduled for 8 a.m. EDT (7 a.m. CDT) on July 22, 2015
ST. PAUL, Minn. & PLEASANTON, Calif.--(BUSINESS WIRE)-- St. Jude Medical (NYSE: STJ) and Thoratec (NASDAQ: THOR) today announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a... More
